Yong Cang
Chief Scientific Officer & Co-founder Degron Therapeutics
Yong Cang, PhD, is the Co-founder and CSO of Degron Therapeutics. He is a scientific leader in targeted protein degradation, ubiquitin ligase biology and cancer immunotherapy with more than 30 publications in top biomedical journals. Dr. Cang pioneers novel molecular glue degrader discovery strategies, with a focus on screening approach development and mechanistic understanding of interactions between molecular glue drugs, ubiquitin ligases and neo-substrates. Dr. Cang is a professor and head of the Laboratory of Targeted Protein Degradation in the School of Life Science and Technology of ShanghaiTech University. He previously was an assistant professor in the NCI-designated Cancer Center of Sanford Burnham Prebys Medical Discovery Institute and a professor of Zhejiang University. Dr. Cang consulted for pharmaceutical industry and venture funds.
Dr. Cang received a BS from Fudan University and a PhD in Molecular Genetics from the Albert Einstein College of Medicine. He completed his postdoctoral training with Professor Stephen Goff at Columbia University and HHMI.
Seminars
Identifying why TPD is the best approach for a target is the first step to becoming the standard of care. In this session, you will explore key factors that determine when a degrader is the best strategy for your target and how to differentiate it from traditional inhibitors. We will cover:
- The unique advantages of degraders: When and why TPD outperforms conventional approaches
- The advantages of a TPD approach versus using inhibition only in regulating BRAF-V600 mutant MAPK pathway signaling in cancer
- Discovery of first-in-class potent and selective oral degraders of KAT6A that demonstrate robust anticancer activity in pre-clinical models
